Recursion Pharmaceuticals (RXRX) Operating Expenses (2020 - 2026)

Recursion Pharmaceuticals has reported Operating Expenses for 7 years, with the latest figure at $135.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 34.51% year-over-year to $135.0 million; the trailing twelve-month figure through Mar 2026 stood at $651.7 million (up 2.82% YoY), and the FY2025 full-year result was $722.8 million, up 34.39% from the prior year.
• Operating Expenses for Q1 2026 stood at $135.0 million, down from $143.9 million in the prior quarter.
• The five-year high for Operating Expenses was $206.1 million in Q1 2025, with the low at $61.3 million in Q1 2022.
• Historically, Operating Expenses has averaged $122.1 million across 5 years, with a median of $110.1 million in 2024.
• Annual changes were most pronounced in 2025 — Operating Expenses jumped 87.15% — and 2026, when it tumbled 34.51%.
• Recursion Pharmaceuticals' Operating Expenses stood at $74.7 million in 2022, then jumped by 47.1% to $109.8 million in 2023, then jumped by 71.47% to $188.3 million in 2024, then dropped by 23.6% to $143.9 million in 2025, then retreated by 6.18% to $135.0 million in 2026.
• The last three Operating Expenses figures came in at $135.0 million (Q1 2026), $143.9 million (Q4 2025), and $177.4 million (Q3 2025), per Business Quant data.